AU2019369397A1 - Compositions and methods comprising IgA antibody constructs - Google Patents

Compositions and methods comprising IgA antibody constructs Download PDF

Info

Publication number
AU2019369397A1
AU2019369397A1 AU2019369397A AU2019369397A AU2019369397A1 AU 2019369397 A1 AU2019369397 A1 AU 2019369397A1 AU 2019369397 A AU2019369397 A AU 2019369397A AU 2019369397 A AU2019369397 A AU 2019369397A AU 2019369397 A1 AU2019369397 A1 AU 2019369397A1
Authority
AU
Australia
Prior art keywords
antibody construct
heavy chain
amino acid
domain
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019369397A
Other languages
English (en)
Inventor
Mark De Boer
Jeannette Henrica Wilhelmina LEUSEN
Geert Jan VAN TETERING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
TigaTx Inc
Original Assignee
UMC Utrecht Holding BV
TigaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV, TigaTx Inc filed Critical UMC Utrecht Holding BV
Publication of AU2019369397A1 publication Critical patent/AU2019369397A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019369397A 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs Pending AU2019369397A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18203183 2018-10-29
US201862752641P 2018-10-30 2018-10-30
US62/752,641 2018-10-30
EP18203183.1 2019-10-29
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Publications (1)

Publication Number Publication Date
AU2019369397A1 true AU2019369397A1 (en) 2021-05-27

Family

ID=70462698

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019369397A Pending AU2019369397A1 (en) 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs

Country Status (9)

Country Link
US (1) US20210332131A1 (enExample)
EP (1) EP3873942A4 (enExample)
JP (2) JP2022506761A (enExample)
KR (1) KR20210096612A (enExample)
CN (1) CN113260632A (enExample)
AU (1) AU2019369397A1 (enExample)
CA (1) CA3118312A1 (enExample)
GB (1) GB2596411B (enExample)
WO (1) WO2020092427A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559A (zh) * 2019-03-27 2022-02-25 蒂嘉特克斯公司 工程化iga抗体及其使用方法
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
CN116829698A (zh) * 2020-12-07 2023-09-29 加利福尼亚大学董事会 通过SIRP-α衔接体的先天免疫细胞沉默
WO2023154730A2 (en) * 2022-02-09 2023-08-17 Exelixis, Inc. Multispecific binding agents and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
JP4653109B2 (ja) * 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
AU2010295661B2 (en) * 2009-09-15 2015-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
EP2791169B1 (en) * 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2925782B1 (en) * 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
HK1217958A1 (zh) * 2013-03-15 2017-01-27 默克专利有限公司 四价双特异性抗体
DK3089994T3 (da) * 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
EP3188758B1 (en) * 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
LT3180363T (lt) * 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
EP3353209B1 (en) * 2015-09-21 2022-03-16 Erasmus University Medical Center Rotterdam Anti-cd47 antibodies and methods of use
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
US11414495B2 (en) * 2016-09-01 2022-08-16 Tiga Tx, Inc. CD20 antibodies
US11267885B2 (en) * 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
DK3658141T3 (da) * 2017-07-24 2023-02-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion
EP3665196B1 (en) * 2017-08-08 2022-10-19 F. Hoffmann-La Roche AG Obinutuzumab treatment of a dlbcl patient subgroup

Also Published As

Publication number Publication date
EP3873942A1 (en) 2021-09-08
WO2020092427A1 (en) 2020-05-07
JP2024170456A (ja) 2024-12-10
GB2596411A (en) 2021-12-29
GB2596411B (en) 2023-09-20
CN113260632A (zh) 2021-08-13
KR20210096612A (ko) 2021-08-05
CA3118312A1 (en) 2020-05-07
GB202107478D0 (en) 2021-07-07
JP2022506761A (ja) 2022-01-17
EP3873942A4 (en) 2022-12-28
US20210332131A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN112513085B (zh) Psma结合剂及其用途
JP6759508B2 (ja) Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2874864C (en) T-cell redirecting bispecific antibodies for treatment of disease
US20160355591A1 (en) Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TWI694086B (zh) 結合人類大麻素１（ｃｂ１）受體之抗體
US20210332131A1 (en) COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS
US12258420B2 (en) Engineered IGA antibodies and methods of use
US20240059789A1 (en) Psma binding proteins and uses thereof
CA2898472A1 (en) Chimeric and humanized anti-histone antibodies
KR102885855B1 (ko) 항-pd-1 항체 및 이의 용도
WO2021008523A1 (zh) 抗tigit抗体及其应用
TWI784932B (zh) 結合人類大麻素1(cb1)受體之抗體
HK40059443A (en) Compositions and methods comprising iga antibody constructs
CA2987644A1 (en) Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CN117580867A (zh) Psma结合蛋白及其用途
HK40067884A (en) Engineered iga antibodies and methods of use